Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China-Based Heparin Prompts Outsourcing Worries

This article was originally published in PharmAsia News

Executive Summary

The problems with Chinese-made ingredients for the heparin blood-thinner drug highlight one peril of drug makers outsourcing production elements. Heparin recalls have been announced in six countries where regulators have been moved to consider the source, China, which itself has increased drug safety efforts. China and India are among developing countries still developing their systems for safeguarding drug production. One American safe-medicine advocate said the heparin problem was "just the tip of the iceberg" where sensitive drugs are concerned. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068174

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel